Glenmark Pharmaceuticals
-
{
- All
- News
- Videos
-
Stock Market Highlights: Markets End In Green As Wall Street, Asian Peers Edge Higher
Sensex Today | Nifty 50 | Stock Market Highlights: GIFT Nifty indicated another positive start for Nifty50 and the Sensex.
-
15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark
ADHD is seen as a chronic and incapacitating disorder that affects a person's everyday functioning.
-
Glenmark Pharma To Sell 75% Stake In Life Sciences To Nirma For $680 Million
Drugmaker Glenmark Pharmaceuticals said on Thursday it would sell a 75% stake in unit Glenmark Life Sciences to detergent maker Nirma for 56.52 billion rupees ($679.84 million).
-
Glenmark Pharmaceuticals Recalls 1,200 Bottles Of "Subpotent" Hypertension Drug In US
Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).
-
Glenmark Pharmaceuticals Gets Final US Approval For Lacosamide Tablet
Homegrown pharma major Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Lacosamide tablet, indicated for prevention and control of seizures.
-
5-Point Guide To The New Nasal Spray For Covid Cleared By India
A nasal spray to treat adult COVID-19 patients has been launched in India after Mumbai-based developers Glenmark Pharmaceuticals received marketing clearances from the Drugs Controller General of India as part of an accelerated approval process.
-
Central Drug Agency Seeks Clarification From Glenmark On Its COVID-19 Drug
The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.
-
Glenmark Launches COVID-19 Drug Favipiravir At Rs 103 Per Tablet
As Glenmark Pharmaceuticals launched antiviral drug Favipiravir for the treatment of mild to moderate COVID-19 cases, medical experts on Saturday cautioned against seeing it as a "magic bullet" to treat the deadly virus but said it will be helpful as it can be orally administered and reduce viral load.
-
Glenmark Pharma Receives 7 Observations From US Regulator On Baddi Unit, Shares Fall
Glenmark Pharmaceuticals said the Baddi unit contributes approximately 10 per cent of the revenue of US sales.
-
High Court To Resume Hearing On Petitions Against Centre's Ban On Drugs
Delhi High Court is likely to resume today the hearing on petitions by over 30 pharmaceutical majors, including Pfizer, Glenmark, Procter and Gamble (P&G) and Cipla, challenging the government's decision to ban sale of some of their fixed dose combination medicines.
-
Delhi High Court Restrains Glenmark from Business of Anti-Diabetes Drugs
In a relief for US drug major Merck Sharp and Dohme (MSD), Delhi High Court today restrained Indian firm Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met, saying it has infringed patent of the American company.
-
Stock Market Highlights: Markets End In Green As Wall Street, Asian Peers Edge Higher
Sensex Today | Nifty 50 | Stock Market Highlights: GIFT Nifty indicated another positive start for Nifty50 and the Sensex.
-
15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark
ADHD is seen as a chronic and incapacitating disorder that affects a person's everyday functioning.
-
Glenmark Pharma To Sell 75% Stake In Life Sciences To Nirma For $680 Million
Drugmaker Glenmark Pharmaceuticals said on Thursday it would sell a 75% stake in unit Glenmark Life Sciences to detergent maker Nirma for 56.52 billion rupees ($679.84 million).
-
Glenmark Pharmaceuticals Recalls 1,200 Bottles Of "Subpotent" Hypertension Drug In US
Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).
-
Glenmark Pharmaceuticals Gets Final US Approval For Lacosamide Tablet
Homegrown pharma major Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Lacosamide tablet, indicated for prevention and control of seizures.
-
5-Point Guide To The New Nasal Spray For Covid Cleared By India
A nasal spray to treat adult COVID-19 patients has been launched in India after Mumbai-based developers Glenmark Pharmaceuticals received marketing clearances from the Drugs Controller General of India as part of an accelerated approval process.
-
Central Drug Agency Seeks Clarification From Glenmark On Its COVID-19 Drug
The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.
-
Glenmark Launches COVID-19 Drug Favipiravir At Rs 103 Per Tablet
As Glenmark Pharmaceuticals launched antiviral drug Favipiravir for the treatment of mild to moderate COVID-19 cases, medical experts on Saturday cautioned against seeing it as a "magic bullet" to treat the deadly virus but said it will be helpful as it can be orally administered and reduce viral load.
-
Glenmark Pharma Receives 7 Observations From US Regulator On Baddi Unit, Shares Fall
Glenmark Pharmaceuticals said the Baddi unit contributes approximately 10 per cent of the revenue of US sales.
-
High Court To Resume Hearing On Petitions Against Centre's Ban On Drugs
Delhi High Court is likely to resume today the hearing on petitions by over 30 pharmaceutical majors, including Pfizer, Glenmark, Procter and Gamble (P&G) and Cipla, challenging the government's decision to ban sale of some of their fixed dose combination medicines.
-
Delhi High Court Restrains Glenmark from Business of Anti-Diabetes Drugs
In a relief for US drug major Merck Sharp and Dohme (MSD), Delhi High Court today restrained Indian firm Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met, saying it has infringed patent of the American company.
